Research To Practice | Oncology Videos

Featuring an interview with Dr Gilles Salles, including the following topics: Epigenetic modifications and the role of EZH2 in the pathobiology of follicular lymphoma (FL) (0:00) Natural history of FL and current treatment landscape in the first-line setting (5:20) Testing approaches for the detection of EZH2 mutations (14:37) Mechanism of action of the EZH inhibitors tazemetostat and valemetostat (18:31) Tazemetostat monotherapy as treatment for relapsed/refractory FL (20:58) Ongoing evaluation of novel treatment approaches with tazemetostat for FL and other lymphomas (25:31) Approved indications for tazemetostat for wild-type FL and FL with EZH2 mutations; sequencing of tazemetostat with bispecific antibodies and CAR T-cell therapy (34:07) Available clinical data with the novel dual EZH1/EZH2 inhibitor valemetostat (42:37) Personal experience with CAR T-cell therapy and perspectives on possible underlying reasons for the development of T-cell lymphoma in patients receiving this treatment (44:35) Management of FL in patients who experience relapse within 24 months of receiving treatment (POD24) (48:25) Myths or misperceptions associated with tazemetostat and other therapies approved in the relapsed FL setting (52:15) Perspectives on the future treatment landscape of FL (54:29) CME information and select publications

Featuring an interview with Dr Stephen V Liu, including the following topics: Management of localized non-small cell lung cancer (NSCLC) (0:00) First-line treatment of advanced NSCLC (10:53) Targeted therapy for patients with NSCLC and actionable genomic alterations (30:24) Recent FDA approvals for NSCLC (37:49) Recent advances in small cell lung cancer (47:14) Lurbinectidin in combination with atezolizumab as front-line maintenance therapy for patients with early-stage SCLC (52:33) CME information and select publications

Featuring perspectives from Dr Tanios Bekaii-Saab and Dr Philip A Philip, including the following topics: Introduction (0:00) Colorectal Cancer, Anal Cancer and Pancreatic Cancer — Dr Philip (1:56) Gastroesophageal Cancers, Hepatocellular Cancer and Biliary Tract Cancers — Dr Bekaii-Saab (41:48) CME information and select publications

Practical Perspectives: Optimizing the Role of BTK Inhibitors in the Management of Mantle Cell Lymphoma | Faculty Presentation — Michael Wang, MD CME information and select publications.

Featuring perspectives from Dr Tycel Phillips and Dr Michael Wang, including the following topics: Introduction: Interface Between Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma (0:00) Key Datasets — Overview and First-Line Therapy (7:16) Faculty Case Presentations — Dr Phillips (27:03) Key Datasets — Relapsed/Refractory Disease (35:40) Faculty Case Presentations — Dr Wang (48:06) CME information and select publications

Featuring a slide presentation and related discussion from Dr Erika Hamilton, including the following topics: Targeted therapies for ER-positive breast cancer (0:00) Clinical data with oral selective estrogen receptor degraders (2:13) Biological rationale for and mechanism of action of proteolysis-targeting chimeras (PROTACs) (7:07) Emerging data with PROTACs for ER-positive advanced breast cancer (9:17) Future directions with PROTACs for breast cancer (19:21) CME information and select publications

Featuring an interview with Dr Erika Hamilton, including the following topics: Pathophysiology and pharmacology of ER-positive breast cancer treatment (0:00) Clinical evidence available with oral selective estrogen receptor degraders (3:46) Mechanism of action of proteolysis-targeting chimeras (PROTACs) (13:22) PROTACs currently in clinical development (16:39) Case: A woman in her late 30s with HR-positive, HER2-negative metastatic breast cancer (mBC) experiencing progression on a CDK4/6 inhibitor (CDK4/6i) and an aromatase inhibitor (AI) (35:09) Case: A woman in her early 70s with HR-positive, HER2-negative mBC that progresses on a CDK4/6i and an AI (41:16) CME information and select publications

Practical Perspectives: Current Management of Chronic Myeloid Leukemia | Faculty Presentation — Jorge Cortes, MD CME information and select publications

Featuring perspectives from Dr Bhavana (Tina) Bhatnagar, Dr Amanda Blackmon, Dr Jorge Cortes, Dr Michael J Mauro and Dr Neil P Shah, including the following topics: Recently presented data affecting the treatment of newly diagnosed chronic myeloid leukemia (CML) (0:00) Case: A man in his mid 40s with newly diagnosed CML with tyrosine kinase inhibitor (TKI) tolerability issues but a good response (24:51) Case: A woman in her mid 80s with chronic-phase CML (CP-CML) with translocation (9;22) (40:26) Case: A woman in her mid 80s with CP-CML and notable comorbidities (43:12) Case: A woman in her early 50s with CP-CML intolerant to dasatinib (51:22) Case: A woman in her late 50s with CP-CML and TKI withdrawal syndrome (1:01:22) Case: A woman in her mid 50s with accelerated-phase CML (1:08:22) Case: A woman in her early 70s with CP-CML and a suboptimal response to second-line TKI (1:17:00) Case: A man in his mid 30s with CP-CML and a complex variant Ph-positive translocation (1:23:24) Case: A man in his mid 30s with CP-CML and a T315I mutation (1:28:55) CME information and select publications

Featuring perspectives from Dr Thierry Alcindor and Dr Mrinal Gounder, including the following topics: Introduction: Biology and Clinical Presentation (0:00) Case: A man in his mid 60s with desmoid fibromatosis — Dr Alcindor (12:36) Tyrosine Kinase Inhibitors (24:51) Gamma Secretase Inhibitors (31:02) Case: A woman in her early 40s with desmoid tumor treated with a gamma secretase inhibitor on a clinical trial — Dr Gounder (46:09) Case: A woman in her late 30s with a large groin desmoid tumor — Dr Gounder (51:52) Case: A woman in her early 30s with desmoid fibromatosis requiring treatment — Dr Alcindor (54:50) CME information and select publications